Proto-Oncogene Proteins c-mdm2
"Proto-Oncogene Proteins c-mdm2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.
| Descriptor ID |
D051736
|
| MeSH Number(s) |
D08.811.464.938.750.562 D12.776.624.664.700.185 D12.776.660.764
|
| Concept/Terms |
Proto-Oncogene Proteins c-mdm2- Proto-Oncogene Proteins c-mdm2
- Proto Oncogene Proteins c mdm2
- c-mdm2, Proto-Oncogene Proteins
- Mdm2 Protein
- Double Minute 2 Protein
- c-mdm2 Proto-Oncogene Protein
- Proto-Oncogene Protein, c-mdm2
- c mdm2 Proto Oncogene Protein
- Murine Double Minute 2 Protein
- Mdm-2 Protein
- Mdm 2 Protein
- MDMX Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-mdm2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-mdm2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-mdm2" by people in this website by year, and whether "Proto-Oncogene Proteins c-mdm2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 1 | 3 |
| 2016 | 2 | 0 | 2 |
| 2018 | 2 | 0 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-mdm2" by people in Profiles.
-
Stapled peptides as scaffolds for developing radiotracers for intracellular targets: Preliminary evaluation of a radioiodinated MDM2-binding stapled peptide in the SJSA-1 osteosarcoma model. Bioorg Med Chem Lett. 2022 06 15; 66:128725.
-
Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. Mol Pharm. 2021 10 04; 18(10):3871-3881.
-
Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells. Pharm Res. 2021 Jun; 38(6):1067-1079.
-
The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma. Head Neck Pathol. 2020 Dec; 14(4):889-898.
-
Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2-p53 interaction. Bioorg Chem. 2019 05; 86:598-608.
-
Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res. 2019 03 01; 25(5):1588-1600.
-
Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents. Bioorg Chem. 2019 02; 82:423-430.
-
Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. Cancer Discov. 2018 11; 8(11):1376-1389.
-
Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res. 2017 Feb 15; 23(4):1036-1048.
-
Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res. 2016 07 15; 22(14):3550-9.